ACI in the Huffington Post: FDA Delays Will Cost Money and Lives

This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs.  These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics.  Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients.  The article calls on the FDA to accelerate its rulemaking and write rules that will permit competitors to enter the market.  That competition will benefits consumers and save lives.  Click here to read and print the Huffington Post piece.

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin